| Area | Highlights (2023‑2025) | |------|-----------------------| | | - A replication‑deficient vesicular stomatitis virus (rVSV) vector expressing MIDV‑679 G‑protein entered Phase I (n = 45) with neutralizing titers >1:160 in 88 % of participants. - mRNA vaccine platform (similar to SARS‑CoV‑2) in pre‑clinical testing shows protection in murine challenge models. | | Antiviral pipelines | - Baloxavir marboxil repurposed; in vitro inhibition at low micromolar concentrations, but in vivo data pending. - Monoclonal antibodies : mAb‑MIDV‑G1 (targets G‑protein) neutralizes >99 % of circulating strains; undergoing GMP manufacturing. | | Diagnostics | - Point‑of‑care isothermal amplification (LAMP) assay under FDA review; expected 2026 clearance. - CRISPR‑Cas13‑based detection kit (SHERLOCK) prototype demonstrates limit of detection 10 copies/µL in whole blood. | | Ecology & Modeling | - Agent‑based models linking climate variables (temperature, precipitation) to vector density predict a 12 % northward expansion by 2035 under current emission trajectories. | | Long‑term sequelae | Prospective cohort of 112 neuroinvasive cases shows persistent neurocognitive deficits at 12 months in 27 % (MoCA scores <26). Ongoing neurorehabilitation trials. |
For those interested in exploring MIDV-679 further, here are some resources: MIDV-679